



Dedicated To Life

August 12, 2023

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street,  
Mumbai-400 001

**Code: 532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, C/1, Block G,  
Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: ZYDUSLIFE**

Re.: **Newspaper publication**

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter ended on June 30, 2023 in Financial Express on August 12, 2023.

Please find the same in order.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

Encl.: As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





## Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Valshnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN : L24230GJ1995PLC025878

Dedicated To Life

### Extract of Consolidated Unaudited Financial Results for the Quarter Ended 30/06/2023

| Sr. No. | Particulars  | Rupees in Million         |                                     |  |                                |
|---------|--|---------------------------|-------------------------------------|--|--------------------------------|
|         |  | 3 Months ended 30/06/2023 | Preceding 3 Months ended 31/03/2023 | Corresponding 3 Months ended 30/06/2022 in the previous year | Previous year ended 31/03/2023 |
|         |  | (Unaudited)               | (Unaudited)                         | (Unaudited)  | (Audited)                      |
| 1       | Total income from operations   | 51,396                    | 50,106                              | 39,643   | 172,374                        |
| 2       | Net Profit for the period before exceptional items and tax                                   | 13,434                    | 10,871                              | 6,839  | 31,939                         |
| 3       | Net Profit for the period after exceptional items but before tax                             | 13,292                    | 4,858                               | 6,810  | 25,897                         |
| 4       | Net Profit for the period from continuing operations   | 10,879                    | 2,988                               | 5,266  | 19,649                         |
| 5       | Loss after tax from discontinued operations  | (10)                      | (22)                                | (83)   | (46)                           |
| 6       | Net Profit for the period after tax and Non-Controlling Interest                             | 10,869                    | 2,966                               | 5,183  | 19,603                         |
| 7       | Total Comprehensive Income for the period after tax and Non-Controlling Interest             | 10,931                    | 3,015                               | 3,608  | 16,459                         |
| 8       | Paid-up equity share capital (Face value Re. 1/-)  | 1,012                     | 1,012                               | 1,024  | 1,012                          |
| 9       | Reserves excluding Revaluation Reserve (i.e. Other Equity)                                   |                           |                                     |  | 174,146                        |
| 10      | Earnings per share for continuing operations (not annualised for the quarter)                |                           |                                     |  |                                |
| a       | Basic (Rs.)  | 10.75                     | 2.95                                | 5.14   | 19.35                          |
| b       | Diluted (Rs.)  | 10.75                     | 2.95                                | 5.14   | 19.35                          |
| 11      | Earnings per share for continuing & discontinued operations (not annualised for the quarter) |                           |                                     |  |                                |
| a       | Basic (Rs.)  | 10.74                     | 2.93                                | 5.06   | 19.30                          |
| b       | Diluted (Rs.)  | 10.74                     | 2.93                                | 5.06   | 19.30                          |

Note:

[1] The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,  
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel  
Managing Director  
DIN: 00131995

Date: August 11, 2023  
Place: Ahmedabad



## Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481  
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com  
CIN : L24230GJ1995PLC025878

Dedicated To Life

### Extract of Consolidated Unaudited Financial Results for the Quarter Ended 30/06/2023

| Sr. No. | Particulars  | Rupees in Million         |                                     |  |                                |
|---------|--|---------------------------|-------------------------------------|--|--------------------------------|
|         |  | 3 Months ended 30/06/2023 | Preceding 3 Months ended 31/03/2023 | Corresponding 3 Months ended 30/06/2022 In the previous year | Previous year ended 31/03/2023 |
|         |  | (Unaudited)               | (Unaudited)                         | (Unaudited)  | (Audited)                      |
| 1       | Total Income from operations   | 51,396                    | 50,106                              | 39,643   | 172,374                        |
| 2       | Net Profit for the period before exceptional items and tax                                   | 13,434                    | 10,871                              | 6,839  | 31,939                         |
| 3       | Net Profit for the period after exceptional items but before tax                             | 13,292                    | 4,858                               | 6,810  | 25,897                         |
| 4       | Net Profit for the period from continuing operations   | 10,879                    | 2,988                               | 5,266  | 19,649                         |
| 5       | Loss after tax from discontinued operations  | (10)                      | (22)                                | (83)   | (46)                           |
| 6       | Net Profit for the period after tax and Non-Controlling Interest                             | 10,869                    | 2,966                               | 5,183  | 19,603                         |
| 7       | Total Comprehensive Income for the period after tax and Non-Controlling Interest             | 10,931                    | 3,015                               | 3,608  | 16,459                         |
| 8       | Paid-up equity share capital (Face value Re. 1/-)  | 1,012                     | 1,012                               | 1,024  | 1,012                          |
| 9       | Reserves excluding Revaluation Reserve (i.e. Other Equity)                                   |                           |                                     |  | 174,146                        |
| 10      | Earnings per share for continuing operations (not annualised for the quarter)                |                           |                                     |  |                                |
| a       | Basic (Rs.)  | 10.75                     | 2.95                                | 5.14   | 19.35                          |
| b       | Diluted (Rs.)  | 10.75                     | 2.95                                | 5.14   | 19.35                          |
| 11      | Earnings per share for continuing & discontinued operations (not annualised for the quarter) |                           |                                     |  |                                |
| a       | Basic (Rs.)  | 10.74                     | 2.93                                | 5.06   | 19.30                          |
| b       | Diluted (Rs.)  | 10.74                     | 2.93                                | 5.06   | 19.30                          |

Note:

[1] The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,  
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel  
Managing Director  
DIN: 00131995

Date: August 11, 2023  
Place: Ahmedabad